Two new studies suggest that nirsevimab (Beyfortus) is 80% to 89% effective in protecting infants from poor respiratory ...

New study shows RSV infection in early infancy can raise asthma risk later, especially in children with allergic family ...

An international team of scientists has found compelling evidence that early-infancy infection with respiratory syncytial virus (RSV) significantly increases the risk of developing childhood asthma.

Nirsevimab is a long-acting monoclonal antibody that provides season-long protection against RSV in infants, reducing ...

The RSV shot isn't suggested for everyone like the flu vaccine is. Here's who is at risk and how to get a shot.

As several European countries are currently detecting respiratory syncytial virus (RSV) infections, ECDC issues rapid ...

The 2025–26 respiratory syncytial virus (RSV) season is shaping up to be a pivotal moment in the fight against this significant global health threat. In just the past 2 years, three products have been ...

An infant immunization for respiratory syncytial virus (RSV) is now available across Canada, but it still has to be paid for ...

As the leaves begin to change and the temperature starts to cool, families are reminded of respiratory syncytial virus (RSV) ...

Background Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections (ALRI) among under-5 ...